SCOTUS to review Amgen-Sanofi patent battle as a proxy for how narrowly pharma patents will need to be written
The Supreme Court has agreed to take up a long-running patent battle between PCSK9 frontrunners Amgen and Sanofi that has spilled into a broader issue of how narrowly pharma patents should be written.
The decision means the highest court in the US agrees to address what’s referred to as the “enablement” requirement, which essentially spells out how a patent should include both a written description of an invention, and the manner and process of making and teaching skilled artisans “to make and use” the invention.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.